Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)

Sponsor
National Cancer Institute, Naples
Study ID
NCT04317092
Phase
PHASE2
Status
Unknown

Conditions

  • COVID-19 Pneumonia

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab Injection — DRUG
    Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose). A second administration (same dose) can be given after 12 hours if respiratory function has not recovered, at discretion of the Investigator.

Study Details

This study project includes a single-arm phase 2 study and a parallel cohort study, enrolling patients with COVID-19 pneumonia.

Key Dates

Start date
Mar 19, 2020
Status verified
Mar 2023
Primary completion
Dec 19, 2023
Completion
Dec 19, 2023

Study Design

Enrollment
402 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: tocilizumab treatment
    All the patients enrolled are treated with tocilizumab.

Primary Outcome Measure

Lethality rate two weeks after registration [ Time Frame: up to 15 days ]

Related Studies